175 related articles for article (PubMed ID: 16474654)
1. Drug insight: Use of docetaxel in prostate and urothelial cancers.
Mackler NJ; Pienta KJ
Nat Clin Pract Urol; 2005 Feb; 2(2):92-100; quiz 1 p following 112. PubMed ID: 16474654
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in prostate cancer.
Small EJ
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Logothetis CJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
[TBL] [Abstract][Full Text] [Related]
6. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (taxotere) in the treatment of prostate cancer.
Beer TM; El-Geneidi M; Eilers KM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
[TBL] [Abstract][Full Text] [Related]
10. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Logothetis C; Millikan R
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):107-11. PubMed ID: 12108893
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of docetaxel in the management of androgen independent prostate cancer.
Khan MA; Carducci M; Partin AW
J Urol; 2003 Nov; 170(5):1709-16. PubMed ID: 14532760
[TBL] [Abstract][Full Text] [Related]
14. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
15. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers.
Berger AP; Niescher M; Fischer-Colbrie R; Pelzer A; Bartsch G; Horninger W
Urol Int; 2004; 73(2):110-2. PubMed ID: 15331892
[TBL] [Abstract][Full Text] [Related]
16. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
17. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Kreis W; Budman D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of taxanes in prostate cancer.
Stein CA
Semin Oncol; 1999 Oct; 26(5 Suppl 17):3-7. PubMed ID: 10604261
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
20. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Bissery MC; Vrignaud P; Lavelle F
Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
